Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.21.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Revenues        
Royalty $ 0 $ 0 $ 0 $ 2,112
Product 25,483 575 75,795 4,201
Total Revenues 25,483 575 75,795 6,313
Operating Expenses        
Research and development 4,445,877 3,180,177 11,968,424 10,567,988
General and administrative 2,426,854 1,080,308 6,053,613 4,292,666
Sales and marketing 715,044 244,510 1,601,816 734,355
Total Operating Expenses 7,587,775 4,504,995 19,623,853 15,595,009
Operating Loss (7,562,292) (4,504,420) (19,548,058) (15,588,696)
Other Income (Expenses)        
Grant income 419,271 0 810,803 98,870
Gain / ( Loss) on disposal of fixed assets 0 200,393 (26,167) 293,595
Interest income 290 2,801 2,503 48,956
Interest expense (38,767) (34,722) (120,636) (91,105)
Total Other Income 380,794 168,472 666,503 350,316
Net Loss (7,181,498) (4,335,948) (18,881,555) (15,238,380)
Net Loss attributable to Non-Controlling Interest 45,065 8,050 102,028 23,396
Net Loss attributable to VolitionRx Limited Stockholders (7,136,433) (4,327,898) (18,779,527) (15,214,984)
Other Comprehensive (Loss) / Income        
Foreign currency translation adjustments (20,875) (573,397) 68,710 (273,791)
Net Comprehensive Loss $ (7,202,373) $ (4,909,345) $ (18,812,845) $ (15,512,171)
Net Loss Per Share - Basic and Diluted attributable to VolitionRx Limited $ (0.13) $ (0.09) $ (0.36) $ (0.34)
Weighted Average Shares Outstanding        
- Basic and Diluted 53,166,781 47,027,011 52,355,681 44,148,793